A prospective study of left ventricle function after treatment with rapid-infusion rituximab in patients with non-Hodgkin lymphoma.
We designed a prospective study to measure the left ventricular ejection fraction of 42 patients with non-Hodgkin lymphoma treated with Rituximab-based chemotherapy in a 1-h infusion. Our patients were not selected on the basis of their cardiac status. Cardiac history and other forms of co-morbidity were to be identified on entry. Before treatment, basal left ventricular ejection function (LVEF) was measured and every 6 months after treatment. Most patients were treated with CHOP-Rituximab combinations (79%). A drop in the post-treatment ejection fraction of over 10% from the pre-treatment base figure was found in 13 patients (31% of the total of the series, 39% of those receiving adriamycin-based chemotherapy). None of the patients without adriamycin had a decrease in LVEF. Three patients with drop >10% recovered normally, but when LVEF decreased by over 15%, which occurred in six patients (14.2%), none of them recovered normal level. Patients with normal systolic function had LVEF with a mean of 64.09 (+/-3.86) and patients with decreased systolic function had LVEF with a mean of 59.38 (+/-5.43). Though the data in this study suggest that rapid-infusion Rituximab does not cause relevant cardiac toxicity, there was a high percentage of reductions in LVEF of over 10%.
Provencio
Mariano
M
Department of Medical Oncology, Puerta de Hierro University Hospital, Madrid, Spain. mprovenciop@gmail.com
Sanchez
Antonio
A
Maximiano
Constanza
C
Cantos
Blanca
B
Méndez
Miriam
M
Bonilla
Félix
F
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D015897:Comorbidity; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D016207:Cytokines / Q000378:metabolism; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006331:Heart Diseases / Q000453:epidemiology; D006801:Humans; D006949:Hyperlipidemias / Q000453:epidemiology; D006973:Hypertension / Q000453:epidemiology; D007262:Infusions, Intravenous / Q000379:methods; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000503:physiopathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000503:physiopathology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011446:Prospective Studies; D000069283:Rituximab; D012907:Smoking / Q000453:epidemiology; D013318:Stroke Volume / Q000187:drug effects*; D013997:Time Factors; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced* / Q000503:physiopathology; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D016207:Cytokines; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone